Liposcience Inc (LPDX) financial statements (2021 and earlier)

Company profile

Business Address 2500 SUMNER BOULEVARD
RALEIGH, NC 27616
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments50
Cash and cash equivalents50
Receivables6
Inventory, net of allowances, customer advances and progress billings0
Inventory0
Other undisclosed current assets1
Total current assets:57
Noncurrent Assets
Property, plant and equipment14
Intangible assets, net (including goodwill)1
Intangible assets, net (excluding goodwill)1
Restricted cash and investments1
Deferred costs0
Other noncurrent assets0
Total noncurrent assets:15
TOTAL ASSETS:72
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2
Accounts payable2
Other undisclosed current liabilities20
Total current liabilities:22
Noncurrent Liabilities
Liabilities, other than long-term debt3
Other liabilities3
Total noncurrent liabilities:3
Total liabilities:24
Stockholders' equity
Stockholders' equity attributable to parent48
Common stock0
Additional paid in capital108
Accumulated deficit(61)
Total stockholders' equity:48
TOTAL LIABILITIES AND EQUITY:72

Income statement (P&L) ($ in millions)

12/31/2013
Revenues
(Revenue, Net)
52
Cost of revenue
(Cost of Goods and Services Sold)
(12)
Other undisclosed gross profit1
Gross profit:42
Operating expenses(52)
Operating loss:(11)
Nonoperating income0
Investment income, nonoperating0
Interest and debt expense(2)
Net loss available to common stockholders, diluted:(13)

Comprehensive Income ($ in millions)

12/31/2013
Net loss:(13)
Comprehensive loss, net of tax, attributable to parent:(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: